Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157
Tel: +81 (0)80-1164-4754
Request a Demo
What our customers are saying
When I think of the future, I think of EvaluatePharma
Global pharmaceutical company
EvaluatePharma Orphan Drug Report 2014
In 2020 orphan drugs are expected to account for 19% of the total share of prescription drug sales excluding generics, reaching $176 billion in annual sales, according to the new EvaluatePharma Orphan Drug Report 2014.
At 11%, growth in the orphan drug market is set to be nearly double the 5% growth rate of the overall prescription market excluding generics.
This year’s report includes for the first time, pricing estimates based on Evaluate’s new USA Sales, Volume and Pricing Analysis. In 2014, the average orphan drug cost per patient per year was $137,782 compared to an average of $20,875 for a non-orphan drug - view infographic here.
The Bio Report Podcast: What's Driving the Booming Market for Orphan Drugs with Jonathan Gardner, Deputy News Editor at EP Vantage.
Key highlights in EvaluatePharma's Orphan Drug Report 2014:
- A record 260 orphan drug designations were granted in the US in 2013
- Orphan drug sales to grow 11% per year through 2020, compared to 5% for drugs (excluding generics) treating larger patient populations
- Vertex’ VX-809 in combination with Kalydeco was 2013’s most valuable R&D orphan drug based on NPV, while Pharmacyclics’ Imbruvica ranked as the most promising new orphan drug approved by the FDA in 2013
- Bristol-Myers Squibb is set to leapfrog Novartis as the leader in orphan drug sales in 2020 thanks to cancer immunotherapeutic Opdivo
- Phase III orphan drug development cost is half that of non-orphans but development time for orphans is not shorter than for non-orphan drugs
- Anticipated return on investment for a Phase III/filed orphan drug is 1.89 times greater than for a non-orphan drug
Download EvaluatePharma Orphan Drug Report 2014
EvaluateMedtech World Preview 2014, Outlook to 2020
EvaluatePharma World Preview 2014, Outlook to 2020
EvaluatePharma Budget-busters: The shift to high-priced innovator drugs in the USA